Bicara Therapeutics Inc (BCAX)

$14.78 +0.52 (3.65%)
Market Cap 816.80M
Revenue (ttm) 0.00
Net Income (ttm) -68.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 460,200
Avg Vol 663,330
Day's Range N/A - N/A
Shares Out 54.78M
Stochastic %K 19%
Beta -0.76
Analysts Strong Sell
Price Target $32.57

Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 468 4219
Address:
116 Huntington Avenue, Suite 703, Boston, United States
JarvisFlow
JarvisFlow Nov. 11 at 2:36 PM
Wells Fargo updates rating for Bicara Therapeutics ( $BCAX ) to Equal-Weight, target set at 8 → 11.
0 · Reply
d_risk
d_risk Nov. 10 at 11:58 PM
$BCAX - Bicara Therapeutics Inc. - 10Q - Updated Risk Factors BCAX’s 10-Q risk factors for 2025 spotlight heightened biotech competition, new AI and companion diagnostic risks, expanded clinical and manufacturing hurdles, reliance on third parties amid geopolitical and regulatory threats, evolving drug pricing laws, and new litigation and tax law exposures, while removing prior risks on data privacy, trade secrets, and certain stockholder issues. #ManufacturingChallenges #ClinicalTrials #AIRisks #Biotechnology #LitigationExposure #GeopoliticalRisk #DrugPricing #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/BCAX/10-Q/2025-11-10
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 27 at 1:10 PM
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology $OTLC $IOBT $NVS $BCAX $PFE https://ibn.fm/3BZ5O
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 20 at 6:08 PM
$BCAX has reverted 3% higher to -13% (~2Mv) moments ago, 11/21 options, follow for more volatility.
0 · Reply
Arcides
Arcides Oct. 20 at 2:37 PM
$BCAX a little haircut on resistance zone....
0 · Reply
topstockalerts
topstockalerts Oct. 13 at 2:09 PM
Shares of Bicara Therapeutics Inc. rose in premarket trading Monday after the company said its cancer therapy ficerafusp alfa received Breakthrough Therapy Designation (BTD) from the FDA. The BTD covers ficerafusp alfa combined with pembrolizumab as a first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma expressing PD-L1, excluding HPV-positive cases. The decision was based on Phase 1/1b data showing a median response duration of 21.7 months and overall survival of 21.3 months, with a favorable safety profile, presented at the 2025 ASCO Annual Meeting. CEO Claire Mazumdar said the designation validates ficerafusp alfa’s best-in-class potential and supports the ongoing FORTIFI-HN01 pivotal trial. The FDA’s BTD aims to accelerate development and review of drugs showing substantial improvement over existing therapies. $BCAX
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 13 at 12:39 PM
$BCAX (+6.3% pre) Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC https://ooc.bz/l/80242
0 · Reply
SlicingOnions
SlicingOnions Oct. 13 at 12:37 PM
$BCAX BTD is now a sell the news event?
1 · Reply
stocktuit
stocktuit Oct. 13 at 12:02 PM
$BCAX it sold off like crazy after the BTD news
0 · Reply
notreload_ai
notreload_ai Oct. 13 at 11:59 AM
$BCAX ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits. https://notreload.xyz/fda-grants-breakthrough-status-promising-head-neck-cancer-treatment/
0 · Reply
Latest News on BCAX
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 7:30 AM EST - 4 days ago

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

Oct 13, 2025, 7:30 AM EDT - 4 weeks ago

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 2 months ago

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 7:30 AM EDT - 3 months ago

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

Jun 11, 2025, 9:42 AM EDT - 5 months ago

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

MRUS

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 4:01 PM EDT - 5 months ago

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Jun 1, 2025, 1:12 PM EDT - 5 months ago

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity

May 23, 2025, 4:17 PM EDT - 6 months ago

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

May 22, 2025, 5:00 PM EDT - 6 months ago

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 6 months ago

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Apr 28, 2025, 4:01 PM EDT - 7 months ago

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:00 AM EDT - 7 months ago

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Bicara: Innovative Precision Tumor Targeting

Apr 19, 2025, 6:22 AM EDT - 7 months ago

Bicara: Innovative Precision Tumor Targeting

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 27, 2025, 7:30 AM EDT - 8 months ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Mar 25, 2025, 4:45 PM EDT - 8 months ago

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:01 PM EST - 9 months ago

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Feb 11, 2025, 4:01 PM EST - 9 months ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 27, 2025, 8:00 AM EST - 10 months ago

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Nov 11, 2024, 4:01 PM EST - 1 year ago

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 16, 2024, 4:01 PM EDT - 1 year ago

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Sep 14, 2024, 5:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

GLXG MBX TDTH XCH ZBIO

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Sep 13, 2024, 1:28 PM EDT - 1 year ago

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Sep 12, 2024, 9:15 PM EDT - 1 year ago

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

Sep 11, 2024, 6:34 PM EDT - 1 year ago

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

Sep 7, 2024, 1:25 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

BIOA PMAX PTHL ZBIO

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Sep 6, 2024, 7:25 AM EDT - 1 year ago

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug

Aug 27, 2024, 2:19 PM EDT - 1 year ago

Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug

JarvisFlow
JarvisFlow Nov. 11 at 2:36 PM
Wells Fargo updates rating for Bicara Therapeutics ( $BCAX ) to Equal-Weight, target set at 8 → 11.
0 · Reply
d_risk
d_risk Nov. 10 at 11:58 PM
$BCAX - Bicara Therapeutics Inc. - 10Q - Updated Risk Factors BCAX’s 10-Q risk factors for 2025 spotlight heightened biotech competition, new AI and companion diagnostic risks, expanded clinical and manufacturing hurdles, reliance on third parties amid geopolitical and regulatory threats, evolving drug pricing laws, and new litigation and tax law exposures, while removing prior risks on data privacy, trade secrets, and certain stockholder issues. #ManufacturingChallenges #ClinicalTrials #AIRisks #Biotechnology #LitigationExposure #GeopoliticalRisk #DrugPricing #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/BCAX/10-Q/2025-11-10
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 27 at 1:10 PM
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology $OTLC $IOBT $NVS $BCAX $PFE https://ibn.fm/3BZ5O
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 20 at 6:08 PM
$BCAX has reverted 3% higher to -13% (~2Mv) moments ago, 11/21 options, follow for more volatility.
0 · Reply
Arcides
Arcides Oct. 20 at 2:37 PM
$BCAX a little haircut on resistance zone....
0 · Reply
topstockalerts
topstockalerts Oct. 13 at 2:09 PM
Shares of Bicara Therapeutics Inc. rose in premarket trading Monday after the company said its cancer therapy ficerafusp alfa received Breakthrough Therapy Designation (BTD) from the FDA. The BTD covers ficerafusp alfa combined with pembrolizumab as a first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma expressing PD-L1, excluding HPV-positive cases. The decision was based on Phase 1/1b data showing a median response duration of 21.7 months and overall survival of 21.3 months, with a favorable safety profile, presented at the 2025 ASCO Annual Meeting. CEO Claire Mazumdar said the designation validates ficerafusp alfa’s best-in-class potential and supports the ongoing FORTIFI-HN01 pivotal trial. The FDA’s BTD aims to accelerate development and review of drugs showing substantial improvement over existing therapies. $BCAX
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 13 at 12:39 PM
$BCAX (+6.3% pre) Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC https://ooc.bz/l/80242
0 · Reply
SlicingOnions
SlicingOnions Oct. 13 at 12:37 PM
$BCAX BTD is now a sell the news event?
1 · Reply
stocktuit
stocktuit Oct. 13 at 12:02 PM
$BCAX it sold off like crazy after the BTD news
0 · Reply
notreload_ai
notreload_ai Oct. 13 at 11:59 AM
$BCAX ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits. https://notreload.xyz/fda-grants-breakthrough-status-promising-head-neck-cancer-treatment/
0 · Reply
MahiMe
MahiMe Oct. 13 at 11:39 AM
$BCAX $BCAX Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC https://www.stocktitan.net/news/BCAX/bicara-therapeutics-announces-ficerafusp-alfa-granted-breakthrough-ku6cy84xketa.html
0 · Reply
DylanGFM
DylanGFM Oct. 13 at 11:33 AM
$ELBM $PMAX $ACON $STI do y'all see what $BCAX just did
1 · Reply
DonCorleone77
DonCorleone77 Oct. 3 at 9:02 PM
$BCAX Bicara Therapeutics files $400M mixed securities shelf
1 · Reply
StockScanners
StockScanners Oct. 2 at 12:44 AM
$BCAX reached 17.38, lets go team
0 · Reply
StockScanners
StockScanners Oct. 1 at 2:15 AM
$BCAX reached 15.83
0 · Reply
StockScanners
StockScanners Sep. 30 at 1:09 AM
$BCAX keep watch if this holds above 12.80
0 · Reply
100Bandz
100Bandz Sep. 29 at 2:57 PM
$BCAX Trending...
0 · Reply
redistributeW
redistributeW Sep. 29 at 12:00 PM
$BCAX Why is Stocktwits deleting posts and not providing quotes for this company?
1 · Reply
GhostTrend
GhostTrend Aug. 23 at 7:05 AM
$BCAX BCA Acquisition Corp is another SPAC with time limitation to find target
1 · Reply
JarvisFlow
JarvisFlow Aug. 19 at 12:00 PM
Piper Sandler has adjusted their stance on Bicara Therapeutics ( $BCAX ), setting the rating to Overweight with a target price of 36.
0 · Reply
Pratik2024
Pratik2024 Jun. 26 at 6:02 PM
$BCAX $CURV $DECK $HNRG $IMMX CURV - PR AF or tomorrow.
0 · Reply